Celastrol Niosome Hydrogel Has Anti-Inflammatory Effect on Skin Keratinocytes and Circulation without Systemic Drug Exposure in Psoriasis Mice

Purpose Psoriasis is an inflammatory skin disease, where keratinocytes play pivotal roles in its pathogenesis. We prepared Celastrol Noisome hydrogel (Cel Nio gel) for the treatment of psoriasis and aimed to study its target site as well as the mechanism. Methods Cel Nio was fabricated with thin-film hydration and sonication, then topically administered to imiquimod (IMQ)-induced psoriasis mice. The concentrations of Cel in the skin, blood and lymphatic system were determined using LC-MS. The anti-psoriasis effect of Cel Nio gel was studied, and the levels of inflammatory cytokines in blood were evaluated by flow cytometry. For the in vitro study, the uptake of Nio by HaCaT cells was quantified with flow cytometry, and the anti-inflammatory effect of Cel on HaCaT cells was detected with qPCR. The expressions of inflammatory factors and Ki-67 in skin were observed by immunofluorescence. Results Cel Nio possessed a particle size of 133 nm with encapsulation efficacy (EE%) of 83.2%. After topical administration of Cel Nio gel to mice, Cel was mainly accumulated in the skin instead of exposure in blood or lymphatic system, while the levels of inflammatory factors in blood had a significant decline. In addition, the preparation of Nio enhanced the uptake by HaCaT cells, and Cel obviously reduced the mRNA levels of inflammatory cytokines in HaCaT cells. Moreover, Cel Nio gel significantly decreased the expression of inflammatory cytokines and Ki-67 in the skin. Conclusion Cel Nio gel achieved the anti-psoriatic effect by inhibiting the inflammation and hyperproliferation of keratinocytes in the skin and further suppressing the systemic inflammation, thus could be a novel topical drug delivery system to treat psoriasis with topical and systemic effects.

[1]  H. Santos,et al.  Microneedles for painless transdermal immunotherapeutic applications. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[2]  J. Ahmad,et al.  Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis , 2020 .

[3]  J. Ahmad,et al.  Nanoemulgel for Improved Topical Delivery of Retinyl Palmitate: Formulation Design and Stability Evaluation , 2020, Nanomaterials.

[4]  Ao Wang,et al.  Dendritic cells: The driver of psoriasis , 2019, The Journal of dermatology.

[5]  Jia-You Fang,et al.  Cutaneous delivery of [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol, an indole-3-carbinol derivative, mitigates psoriasiform lesion by blocking MAPK/NF-κB/AP-1 activation. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Ying Zheng,et al.  Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity. , 2019, Colloids and surfaces. B, Biointerfaces.

[7]  Jiyong Liu,et al.  Transdermal drug delivery of triptolide‐loaded nanostructured lipid carriers: Preparation, pharmacokinetic, and evaluation for rheumatoid arthritis , 2019, International journal of pharmaceutics.

[8]  Jia Liu,et al.  Transdermal delivery system of nanostructured lipid carriers loaded with Celastrol and Indomethacin: optimization, characterization and efficacy evaluation for rheumatoid arthritis , 2018, Artificial cells, nanomedicine, and biotechnology.

[9]  C. Albanesi,et al.  The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis , 2018, Front. Immunol..

[10]  O. Abdallah,et al.  Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol. , 2018, International journal of pharmaceutics.

[11]  S. Jacob,et al.  Preparation and evaluation of niosome gel containing acyclovir for enhanced dermal deposition , 2017, Journal of liposome research.

[12]  H. Tong,et al.  Enhanced topical penetration, system exposure and anti‐psoriasis activity of two particle‐sized, curcumin‐loaded PLGA nanoparticles in hydrogel , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Mandip Singh,et al.  Novel amphiphilic lipid augments the co‐delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[14]  J. Krueger,et al.  Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. , 2017, Annual review of medicine.

[15]  Yi Fritz,et al.  Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury. , 2016, Immunity.

[16]  S. Feldman,et al.  Current challenges and emerging drug delivery strategies for the treatment of psoriasis , 2016, Expert opinion on drug delivery.

[17]  Q. Lu,et al.  The Inflammatory Response in Psoriasis: a Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.

[18]  L. Iversen,et al.  Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  Ahmed Abdelbary,et al.  Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. , 2015, International journal of pharmaceutics.

[20]  Ying Zhang,et al.  Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris: A Randomized Clinical Trial , 2015, Chinese medical journal.

[21]  J. O’Shea,et al.  Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ , 2015, Clinical immunology.

[22]  R. Shikiar,et al.  Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials , 2003, Health and Quality of Life Outcomes.

[23]  S. Turley,et al.  Stromal infrastructure of the lymph node and coordination of immunity. , 2015, Trends in immunology.

[24]  S. Chaudhari,et al.  Niosomes: novel sustained release nonionic stable vesicular systems--an overview. , 2012, Advances in colloid and interface science.

[25]  J. Q. Rosso,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions , 2012 .

[26]  G. P. Kumar,et al.  Nonionic surfactant vesicular systems for effective drug delivery—an overview , 2011 .

[27]  G. Sethi,et al.  Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. , 2011, Cancer letters.

[28]  Qiaojun He,et al.  Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol , 2010, Cancer investigation.

[29]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[30]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. , 2009, Journal of the American Academy of Dermatology.

[31]  C. Albanesi,et al.  Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. , 2007, Clinics in dermatology.

[32]  M. Cesta Normal Structure, Function, and Histology of the Spleen , 2006, Toxicologic pathology.

[33]  P. Lipsky,et al.  The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. , 2000, Rheumatic diseases clinics of North America.